The first biologic treatment for psoriasis, Amevive (Am-uh-veev), is now approved and on the market

December 2004

The first biologic treatment for psoriasis, Amevive (Am-uh-veev), is now approved and on the market.

Amevive (alefacept) is an immunosuppressant. It inhibits the T-cells that contribute to psoriasis.

It's given IM once weekly for 12 weeks...followed by a 12-week break. Some patients will be taught to self-inject IM at home.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Patients benefit when community and hospital pharmacies share info from patient profiles
Men's Health statins might decrease libido or cause erectile dysfunction
Diabetes & Endocrinology Sensipar (cinacalcet), a new drug for dialysis patients
Osteoporosis Is it important to take magnesium along with calcium
Osteoporosis Reps will tout new evidence that Fosamax increases bone density better than Actonel
Dermatology The first biologic treatment for psoriasis, Amevive (Am-uh-veev), is now approved and on the market
Respiratory & Allergy patients aren't aware when their metered-dose inhalers are empty
NATURAL alternatives to Vioxx
Gastroenterology gastric acid-suppressing drugs increasing the risk of pneumonia
Ophthalmology Zymar, another new quinolone ophthalmic antibiotic
Cardiology whether ACE inhibitors are beneficial for patients with STABLE coronary artery disease
Natural Health Products Libracol with HEP 30
Vitamins & Minerals vitamin E supplements might actually INCREASE mortality
whether atenolol should be used for hypertension
Practice End of year is a good time to reflect on trustworthy drug information that is relevant to practice.